SEC Filing Analysis: Atara Biotherapeutics, Inc. (ATRA)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Chief Accounting Officer executed a small, automatic sale of shares to cover tax liabilities associated with vesting restricted stock units.
• Market Impact: Neutral. This is a routine, non-discretionary transaction with negligible financial impact.

Company Information

Field	Value
Company	Atara Biotherapeutics, Inc.
Ticker Symbol	ATRA
CIK	0001604464
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	Grant-Huerta Yanina
CIK	0002064348
Title/Position	Chief Accounting Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-11-17
Transaction Code	S
Security Type	Common Stock
Shares Involved	1,804
Price Per Share	$13.19 (Weighted Avg)
Total Value	$23,788
Shares Owned After	33,454
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$23,788
% of Market Cap	0.024%
Shares Transacted	1,804
% of Shares Outstanding	Not Available
Post-Transaction Ownership	33,454 shares
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The transaction value of approximately $24k is negligible against Atara's market capitalization of $100 million.
• Transaction Significance: The sale represents a mere 0.024% of the company's market cap, falling far below any threshold for significance. The sale constituted approximately 5.1% of the insider's holdings.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction was an automatic 'sell-to-cover' action to satisfy tax obligations, as disclosed in the filing's footnotes. Such sales are not indicative of an insider's sentiment towards the company's future prospects.

Volume & Sentiment

• Expected Volume Impact: Negligible. The number of shares sold is too small to impact trading volume.
• Sentiment Indicator: Neutral. This is a routine, non-discretionary transaction that carries no market sentiment.

Additional Context

Transaction Notes

• Special Circumstances: Footnote F1 explicitly states, "Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement." This confirms the non-discretionary nature of the sale.